Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.
|Articles|September 20, 2017
Spectrum Chemical in Distribution Deal with Cole-Parmer
Author(s)BioPharm International Editors
Spectrum Chemical announced an agreement with Cole-Parmer for the distribution of Spectrum’s USP fine chemicals.
Advertisement
On Sep. 20, 2017, Spectrum Chemical, a manufacturer and distributor of fine chemicals, laboratory equipment, and supplies, announced a distribution agreement with Cole-Parmer, a manufacturer and distributor of fluid handling products, instrumentation, equipment, and supplies. Under the agreement, Cole Parmer will distribute Spectrum’s USP fine chemicals.
“The addition of Cole-Parmer to our distribution network adds laboratory instrument expertise and brand strength to our portfolio,” said Randy Burg, president and CEO of Spectrum, in a company press release.
Brian Buzinski, director of lab essentials business unit at Cole Parmer added, “As a trusted name in quality chemicals for more than four decades, we are happy to now offer Spectrum products to Cole-Parmer’s customers.”
Source:
Advertisement
Related to this article
Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.
Doubled drug substance capacity at Alvotech's Reykjavik, Iceland, site aims to secure steady US supply of the Humira biosimilar Simlandi.
The glucagon/GLP-1 dual agonist hit both weight loss endpoints in phase 3, though gastrointestinal discontinuations and competitor data temper the readout.
CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on Abogen's RNA platform.
Advertisement
Advertisement